Bioaffinity Technologies, Stock Today
| BIAF Stock | USD 0.26 0.03 10.34% |
PerformanceVery Weak
| Odds Of DistressVery High
|
BioAffinity Technologies, is trading at 0.26 as of the 19th of March 2025. This is a 10.34% down since the beginning of the trading day. The stock's lowest day price was 0.26. BioAffinity Technologies, has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 17th of February 2025 and ending today, the 19th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 1st of September 2022 | Category Healthcare | Classification Health Care |
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company was founded in 2014 and is based in San Antonio, Texas. Bioaffinity Technologies operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. The company has 15.48 M outstanding shares of which 251.91 K shares are currently shorted by private and institutional investors with about 1.43 trading days to cover. More on bioAffinity Technologies,
Moving against BioAffinity Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
BioAffinity Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Diagnostics & Research, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| BioAffinity Technologies, can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand BioAffinity Technologies,'s financial leverage. It provides some insight into what part of BioAffinity Technologies,'s total assets is financed by creditors.
LiquiditybioAffinity Technologies, currently holds 1.58 M in liabilities. bioAffinity Technologies, has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about BioAffinity Technologies,'s use of debt, we should always consider it together with its cash and equity.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
bioAffinity Technologies, (BIAF) is traded on NASDAQ Exchange in USA. It is located in 22211 West Interstate 10, San Antonio, TX, United States, 78257 and employs 75 people. BioAffinity Technologies, is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 19.81 M. bioAffinity Technologies, conducts business under Biotechnology sector and is part of Health Care industry. The entity has 15.48 M outstanding shares of which 251.91 K shares are currently shorted by private and institutional investors with about 1.43 trading days to cover.
bioAffinity Technologies, currently holds about 214.4 K in cash with (6.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08.
Check BioAffinity Technologies, Probability Of Bankruptcy
Ownership AllocationBioAffinity Technologies, holds a total of 15.48 Million outstanding shares. bioAffinity Technologies, retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check BioAffinity Ownership Details
BioAffinity Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Tower Research Capital Llc | 2024-12-31 | 6.3 K | |
| Oarsman Capital, Inc | 2024-12-31 | 2.4 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 500 | |
| Clear Street Llc. | 2024-09-30 | 100.0 | |
| Bank Of America Corp | 2024-12-31 | 84.0 | |
| Jpmorgan Chase & Co | 2024-12-31 | 21.0 | |
| Ground Swell Capital, Llc | 2024-09-30 | 0.0 | |
| Ubs Group Ag | 2024-09-30 | 0.0 | |
| Renaissance Technologies Corp | 2024-09-30 | 0.0 | |
| Vanguard Group Inc | 2024-12-31 | 260.9 K | |
| Geode Capital Management, Llc | 2024-12-31 | 99.6 K |
BioAffinity Technologies, Historical Income Statement
BioAffinity Stock Against Markets
BioAffinity Technologies, Corporate Management
| Timothy JD | Secretary VP | Profile | |
| Dallas Coleman | National Sales | Profile | |
| William Bauta | Senior Therapeutics | Profile | |
| Maria JD | President, Founder | Profile | |
| Xavier MS | VP Operations | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in bioAffinity Technologies,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in BioAffinity Stock please use our How to Invest in BioAffinity Technologies, guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioAffinity Technologies,. If investors know BioAffinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioAffinity Technologies, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.91) | Revenue Per Share | Quarterly Revenue Growth 120.474 | Return On Assets | Return On Equity |
The market value of bioAffinity Technologies, is measured differently than its book value, which is the value of BioAffinity that is recorded on the company's balance sheet. Investors also form their own opinion of BioAffinity Technologies,'s value that differs from its market value or its book value, called intrinsic value, which is BioAffinity Technologies,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioAffinity Technologies,'s market value can be influenced by many factors that don't directly affect BioAffinity Technologies,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioAffinity Technologies,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if BioAffinity Technologies, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioAffinity Technologies,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.